ArticleACS omega2016
Gadolinium-Functionalized Peptide Amphiphile Micelles for Multimodal Imaging of Atherosclerotic Lesions.
Article in ACS omega, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- Selective blockade of microRNA-31-5p/calcitonin receptor interaction reverses established atrial fibrosis and atrial arrhythmia substrate.Research square · 2026Article
- Application of Nanomaterials in Early Imaging and Advanced Treatment of Atherosclerosis.Chemical & biomedical imaging · 2025Review
- Review
- Molecular imaging nanoprobes and their applications in atherosclerosis diagnosis.Theranostics · 2024Review
- Review
- Atherosclerosis treatment with nanoagent: potential targets, stimulus signals and drug delivery mechanisms.Frontiers in bioengineering and biotechnology · 2023Review
- Advances in imaging and treatment of atherosclerosis based on organic nanoparticles.APL bioengineering · 2022Review
- Fibrin-Targeted Nanoparticles for Finding, Visualizing and Characterizing Blood Clots in Acute Ischemic Stroke.Pharmaceutics · 2022Article
- Nanoparticles in the diagnosis and treatment of vascular aging and related diseases.Signal transduction and targeted therapy · 2022Review
- Transdermal Delivery of Kidney-Targeting Nanoparticles Using Dissolvable Microneedles.Cellular and molecular bioengineering · 2020Article
- Application of Nanomaterials in Biomedical Imaging and Cancer Therapy.Nanomaterials (Basel, Switzerland) · 2020Review
- Targeting Dysfunctional Vascular Endothelial Cells Using Immunoliposomes Under Flow Conditions.Cellular and molecular bioengineering · 2020Article
- Collagenase-Cleavable Peptide Amphiphile Micelles as a Novel Theranostic Strategy in Atherosclerosis.Advanced therapeutics · 2020Article
- Hydroxyapatite-binding micelles for the detection of vascular calcification in atherosclerosis.Journal of materials chemistry. B · 2019Article
- Calcium-binding nanoparticles for vascular disease.Regenerative engineering and translational medicine · 2019Article
- Application of the Nano-Drug Delivery System in Treatment of Cardiovascular Diseases.Frontiers in bioengineering and biotechnology · 2019Review
- Hybrid, metal oxide-peptide amphiphile micelles for molecular magnetic resonance imaging of atherosclerosis.Journal of nanobiotechnology · 2018Article
- Shape Effects of Peptide Amphiphile Micelles for Targeting Monocytes.Molecules (Basel, Switzerland) · 2018Article
- Theranostic Nanoparticles for Tracking and Monitoring Disease State.SLAS technology · 2018Review
- Progress Toward the Clinical Translation of Bioinspired Peptide and Protein Assemblies.Advanced healthcare materials · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The leading causes of morbidity and mortality globally are cardiovascular diseases, and nanomedicine can provide many improvements including disease-specific targeting, early detection, and local delivery of diagnostic agents. To this end, we designed fibrin-binding, peptide amphiphile micelles (PAMs), achieved by incorporating the targeting peptide cysteine-arginine-glutamic acid-lysine-alanine (CREKA), with two types of amphiphilic molecules containing the gadoliniuim (Gd) chelator diethylenetriaminepentaacetic acid (DTPA), DTPA-bis(stearylamide)(Gd), and 1,2-distearoyl-
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.